@ Newsroom | SEBIO

Kailos Genetics and Huntsman Cancer Institute Awarded $2.4 Million Grant for ctDNA Test Development

Posted by on Jun 23, 2016 in Newsroom | 0 comments

HUNTSVILLE, AL. – Kailos Genetics, a personalized medicine information company offering leading-edge gene-based testing, announced on June 22,2016, that they have entered into a collaboration with Huntsman Cancer Institute (HCI) at the University of Utah to develop a clinical-grade test for circulating tumor DNA (ctDNA). Backed by a $2.4 million grant from the National Institutes of Health (NIH), the minimally invasive test will be used to monitor patients for breast cancer disease recurrence. Approximately 1.5 million women in the United States will be monitored for disease recurrence...

Read More

Chesterfield biotechnology company relocating to Virginia Beach

Posted by on Jun 22, 2016 in Newsroom | 0 comments

RICHMOND, VA. – A Chesterfield County-based biotechnology startup is leaving the Richmond area for the beach. Sanyal Biotechnology announced Tuesday that it has signed a lease to move its corporate headquarters to Virginia Beach, where it will occupy a 1,500-square-foot facility in the VABeachBio Accelerator at the Regional Health Professions Center at Tidewater Community College. The Virginia Beach Development Authority also has awarded Sanyal Biotechnology a $25,000 Economic Development Investment Program grant. The move will take place July 1 and is especially appealing to Sanyal...

Read More

Piedmont biotech offers $11,000 research prize

Posted by on Jun 17, 2016 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. – How will your research heal, fuel or feed the world one day? That’s the $11,000 question being asked by Greensboro’s newest life science company, SoBran Bioscience, in partnership with the Piedmont Triad Office of the North Carolina Biotechnology Center. As announced in February 2016, SoBran, a 500-employee privately held contract research organization headquartered in Fairfax, Va., has opened a new animal care and research facility in partnership with North Carolina Agricultural and Technical State University. As part of the opening celebration,...

Read More

Report: Key indicators show Alabama bioscience industry expanding

Posted by on Jun 14, 2016 in Newsroom | 0 comments

Alabama’s bioscience industry is robust, and key indicators show the sector is growing to support new, high-paying jobs, according to a report from TEConomy Partners LLC and theBiotechnology Innovation Organization, or BIO. The “Value of Bioscience Innovation in Growing Jobs and Improving Quality of Life 2016” Report examines metrics including the number of employees and companies in the field, wages, academic research and development expenditures, patents, and venture capital investments. The Alabama biotech report found: Alabama’s bioscience industry employment totaled nearly...

Read More

Espero Pharmaceuticals Receives FDA Approval for GONITRO™ (Nitroglycerin) Sublingual Powder

Posted by on Jun 14, 2016 in Newsroom | 0 comments

JACKSONVILLE, FL. – Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. With this approval, GONITROTM is the first and only short-acting nitrate in a stabilized crystal granule form available in single dose packets. “The FDA approval of GONITRO™ enhances the treatment options available to the more than 8 million U.S. patients...

Read More

AGTC Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-linked Retinitis Pigmentosa

Posted by on Jun 10, 2016 in Newsroom | 0 comments

GAINESVILLE, FL. & CAMBRIDGE, MA. – Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the European Commission (EC) has granted an orphan medicinal product designation to its investigational gene therapy product candidate for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. XLRP is an inherited condition that causes progressive vision loss, beginning with night blindness...

Read More